Research Article
Open Access
MDCO-700, a New Generation Anesthetic: Evaluation of Two
Formulations in Sprague-Dawley Rats
Mojgan Sabet*, Ziad Tarazi, Nitin Joshi, Brad Zerler, Douglas E. Rains and David C. Griffith
The Medicines Company, 3013 Science Park Rd, San Diego, USA. CA 92121-1309.
*Corresponding author: Mojgan Sabet, The Medicines Company, 3013 Science Park Rd, San Diego, USA, CA 92121-1309. Tel: 858-875-6679; Fax:
858-875-2851; E-mail:
@
Received: April 18 2018; Accepted: May 30 2018; Published: June 04 2018
Citation: Sabet M (2018) MDCO-700, a New Generation Anesthetic: Evaluation of Two Formulations in Sprague-Dawley Rats. SOJ Anesthesiol Pain Manag. 5(1): 1-5. DOI: 10.15226/2374-684X/5/1/00156
Abstract Top
Background: MDCO-700(cyclopropyl-methoxycarbonyl
metomidate) is a novel, potent, positive allosteric modulator of
the γ-Aminobutyric Acid type A (GABAA) receptor currently being
developed for general anesthesia and procedural sedation. Early
studies were conducted with a formulation that had to be stored
at frozen conditions. A new formulation was developed to enable
storage under refrigerated conditions. The original formulation
(MDCO-700-F1) and the new formulation (MDCO-700-F2) were
both prepared in Sulfobutyl ether-β-cyclodextrin (SBEβCD), however
MDCO-700-F2 was prepared at a lower concentration and higher pH
in order to improve long-term storage stability. The objective of this
study was to compare the anesthetic effects of both formulations in
male Sprague-Dawley rats.
Methods: Rats received doses of either MDCO-700-F1 or MDCO- 700-F2 ranging from1 to 6 mg/kg. Doses were administered as an intravenous bolus over 5 seconds via surgically implanted jugular vein cannulas. Immediately after the bolus, rats were turned supine and the clinical signs of anesthesia were monitored until they returned to normal behavior. The relationships between dose and the anesthetic effects of MDCO-700 were analyzed and modeled using pharmacodynamic models.
Results: Both formulations rapidly produced similar dosedependent depths of sedation with increasing effect at higher doses. The time required for recovery, as assessed using qualitative and semi-quantitative metrics, increased with increasing dose and was similar for the two formulations. The dose-response for all measured parameters including arousal level, duration of action and full recovery were similar for both formulations.
Conclusion: Under the conditions of this study, the data demonstrates that both formulations of MDCO-700 produced equivalent anesthetic effects in rats across the concentration range tested. These results suggest that either formulation can be used for ongoing clinical development.
Key words: MDCO-700; anesthetic; Sprague-Dawley rats;
Methods: Rats received doses of either MDCO-700-F1 or MDCO- 700-F2 ranging from1 to 6 mg/kg. Doses were administered as an intravenous bolus over 5 seconds via surgically implanted jugular vein cannulas. Immediately after the bolus, rats were turned supine and the clinical signs of anesthesia were monitored until they returned to normal behavior. The relationships between dose and the anesthetic effects of MDCO-700 were analyzed and modeled using pharmacodynamic models.
Results: Both formulations rapidly produced similar dosedependent depths of sedation with increasing effect at higher doses. The time required for recovery, as assessed using qualitative and semi-quantitative metrics, increased with increasing dose and was similar for the two formulations. The dose-response for all measured parameters including arousal level, duration of action and full recovery were similar for both formulations.
Conclusion: Under the conditions of this study, the data demonstrates that both formulations of MDCO-700 produced equivalent anesthetic effects in rats across the concentration range tested. These results suggest that either formulation can be used for ongoing clinical development.
Key words: MDCO-700; anesthetic; Sprague-Dawley rats;
Introduction
Etomidate, propofol, midazolam and thiopental are commonly
used anesthetic and sedative agents that act by enhancing
the function of γ-Aminobutyric Acid (GABAA) receptors in the
central nervous system [1]. Among these four agents, propofol
and etomidate are the most commonly used agents to induce
anesthesia at the start of surgery. Etomidate is used as an
anesthetic agent in emergency departments and intensive care
units. It produces a rapid onset of anesthesia with minimum
effects on both heart rate and blood pressure and, therefore, can
be safely used in patients with valvular or ischemic heart disease
[2]. Unfortunately, the suppression of adrenocortical function by
etomidate has raised a major concern among clinicians [3].
Cyclopropyl-methoxycarbonyl metomidate, also known as MDCO-700, is currently being developed for general anesthesia and procedural sedation. It offers the promise of rapid onset and offset of anesthetic effects without a significant impact on respiration, hemodynamics or adrenocortical suppression. While MDCO-700 possesses these favorable pharmacologic properties, it is poorly soluble in water at pH greater than ~2.5 and is unstable in aqueous solution. Therefore, MDCO-700 is formulated using Sulfobutyl ether-β-cyclodextrin (SBEβCD) as a solubilizing agent. The initial formulation (MDCO-700-F1) was developed at a concentration of 10 mg/ml in 10% SBEβCD at a pH of 3.0. However, this formulation had to be stored frozen at -20°C for long term storage stability. To overcome this limitation, MDCO-700was reformulated at 4 mg/mL in 10% SBEβCD at a pH of 5.5 (MDCO-700-F2). This new formulation offered the benefit of long term storage under refrigerated conditions instead of frozen at -20°C. A comparison of the formulations is provided in Table 1.
Cyclopropyl-methoxycarbonyl metomidate, also known as MDCO-700, is currently being developed for general anesthesia and procedural sedation. It offers the promise of rapid onset and offset of anesthetic effects without a significant impact on respiration, hemodynamics or adrenocortical suppression. While MDCO-700 possesses these favorable pharmacologic properties, it is poorly soluble in water at pH greater than ~2.5 and is unstable in aqueous solution. Therefore, MDCO-700 is formulated using Sulfobutyl ether-β-cyclodextrin (SBEβCD) as a solubilizing agent. The initial formulation (MDCO-700-F1) was developed at a concentration of 10 mg/ml in 10% SBEβCD at a pH of 3.0. However, this formulation had to be stored frozen at -20°C for long term storage stability. To overcome this limitation, MDCO-700was reformulated at 4 mg/mL in 10% SBEβCD at a pH of 5.5 (MDCO-700-F2). This new formulation offered the benefit of long term storage under refrigerated conditions instead of frozen at -20°C. A comparison of the formulations is provided in Table 1.
Table 1: Comparison of MDCO-700 Formulations
Component |
MDCO-700-F1 |
MDCO-700-F2 |
MDCO-700 |
10 mg/mL |
4 mg/mL |
Sulfobutyl ether-β-cyclodextrin (SBEβCD) |
100 mg/mL (10%) |
100 mg/mL (10%) |
Meglumine |
Added to adjust pH to 3 |
Not used |
Citric Acid anhydrous |
Not used |
0.55 mg/mL |
Sodium Citrate |
Not used |
1.84 mg/mL |
Sodium Hydroxide |
Not used |
Added to adjust pH to 5.5 |
The objective of this study was to compare the anesthetic
effects of these two formulations of MDCO-700 in male Sprague-
Dawley rats.
Materials and Methods
Animals
All animal studies were performed under a protocol approved
by an Institutional Animal Care and Use Committee (IACUC). Male
Sprague-Dawley rats (Envigo Laboratories, Indianapolis, IN),
weighing between 300–350 grams, had jugular vein cannulas
(JVC) surgically implanted by the vendor prior to receipt. Upon
receipt, the animals were individually housed in a room with a
controlled environment and acclimated to laboratory conditions
for at least 24 hours prior to the start of dosing. Animals were
provided food and water ad libitum. Throughout all procedures,
animals were kept warm using heating pads to avoid hypothermia.
During the experiment, animals were manually restrained to
prepare the cannula, after which they were free to move during
and following administration of the dose.
Treatment
MDCO-700-F1 was manufactured by The Medicines Company
and was stored frozen at -20°C until use. MDCO-700-F2 was
manufactured by The Medicines Company and was kept
refrigerated until use. Prior to dosing, each formulation was
brought to room temperature approximately 30 minutes prior to
administration.
Dosing
After acclimation, male rats were randomized (n=4) to
one of 10 treatment groups. Rats received 1,2,3,4 or 6 mg/
kg of either MDCO-700-F1 or MDCO-700-F2 (Table 2). Each
dose was administered by intravenous bolus over 5 seconds
via the JVC using an insulin syringe (EXEL INT, Redondo
Beach, CA) affixed with a blunt needle. The total time of
dosing was carefully controlled to be 5 seconds to ensure
equipotent dosing (mg/kg/min) between the two formulations.
Table 2: Study groups, doses and dose volumes
Group |
Compound |
Conc. |
# of Animals |
Dose |
Dose Volume |
1 |
MDCO-700-F1 |
10 |
4 |
1 |
0.10 |
2 |
MDCO-700-F1 |
10 |
4 |
2 |
0.20 |
3 |
MDCO-700-F1 |
10 |
4 |
3 |
0.30 |
4 |
MDCO-700-F1 |
10 |
4 |
4 |
0.40 |
5 |
MDCO-700-F1 |
10 |
4 |
6 |
0.60 |
6 |
MDCO-700-F2 |
4 |
4 |
1 |
0.25 |
7 |
MDCO-700-F2 |
4 |
4 |
2 |
0.50 |
8 |
MDCO-700-F2 |
4 |
4 |
3 |
0.75 |
9 |
MDCO-700-F2 |
4 |
4 |
4 |
1.00 |
10 |
MDCO-700-F2 |
4 |
4 |
6 |
1.50 |
Pharmacodynamic Measures: Clinical Signs of
Anesthesia
Immediately after the dose, rats were turned supine, and
the following clinical signs were monitored and recorded for all
animals: a) arousal level, b) time to emergence from anesthesia,
c) time to sternal recumbency, d) time to recovery from loss of
righting reflex (LORR) and e) time to return to normal (alert and
displays exploratory behavior).
Arousal level was scored using a subjective numerical anesthesia scale (Table 3). The arousal level was scored between 1 (deeply unconscious and sedated) to a score of 5 (but sluggish and not fully normal). In some animals, the arousal level was between 1 and 2 because rats were not deeply anesthetized but appeared sedated. These data were reported at 1.5.
Arousal level was scored using a subjective numerical anesthesia scale (Table 3). The arousal level was scored between 1 (deeply unconscious and sedated) to a score of 5 (but sluggish and not fully normal). In some animals, the arousal level was between 1 and 2 because rats were not deeply anesthetized but appeared sedated. These data were reported at 1.5.
Table 3: Behavioral signs associated with Arousal level
Arousal Level |
Behavioral Signs |
1 |
Animal appears unconscious. |
2 |
Animal appears sedated but not unconscious. |
3 |
Animal appears sedated and responds to environmental stimuli. |
4 |
Animal appears sedated and exhibits signs of excitation such as involuntary movements. |
5 |
Animal is not sedated but slow and sluggish with some exploratory behavior with periods of inactivity. |
The duration of effect was subcategorized to time to emergence
(head up and turning around), time to sternal recumbency (only
front paws on ground), time to recovery from LORR (the animal
turning and supporting weight with all 4 paws on ground) and
finally, time to return to normal or full recovery from anesthesia.
Pharmacodynamic Modeling
The relationship between the dose and arousal level was fit to
an inhibitory effect sigmoid Emax model (Phoenix® WinNonlin®
v 6.3, Certara, Mountain View, CA) as follows:
Arousal level = E0 - (Imax * Xγ) / (Xγ + IC50γ)
where E0 is the effect when X is equal to zero, Imax is the maximum effect on arousal level, X is the dose, EC50 is the dose (X) corresponding to 50% of the maximum effect and γ is the sigmoidicity factor which controls the steepness of the curve.
The relationship between duration of anesthetic effects and dose was fit using a sigmoid Emax model (Phoenix® WinNonlin® v 6.3, Certara, Mountain View, CA) as follows:
E= (Emax* Xγ) / (Xγ + EC50γ)
where E is the duration of anesthetic effect (emergence from anesthesia, sternal recumbency, recovery of LORR, return to normal), Emax is the maximum duration of anesthetic effect, X is the dose, EC50 is the dose (X) corresponding to 50% of the maximum effect and γ is the sigmoidicity factor which controls the steepness of the curve.
Arousal level = E0 - (Imax * Xγ) / (Xγ + IC50γ)
where E0 is the effect when X is equal to zero, Imax is the maximum effect on arousal level, X is the dose, EC50 is the dose (X) corresponding to 50% of the maximum effect and γ is the sigmoidicity factor which controls the steepness of the curve.
The relationship between duration of anesthetic effects and dose was fit using a sigmoid Emax model (Phoenix® WinNonlin® v 6.3, Certara, Mountain View, CA) as follows:
E= (Emax* Xγ) / (Xγ + EC50γ)
where E is the duration of anesthetic effect (emergence from anesthesia, sternal recumbency, recovery of LORR, return to normal), Emax is the maximum duration of anesthetic effect, X is the dose, EC50 is the dose (X) corresponding to 50% of the maximum effect and γ is the sigmoidicity factor which controls the steepness of the curve.
Statistical Analysis
The anesthetic effects of both MDCO-700 formulations were
compared by unpaired t-test (Graph Pad Prism version 6.03),
respectively. A p value of < 0.05 was considered statistically
significant.
Results
Clinical signs of anesthesia for both formulations are shown
in Tables 4 and 5. With the exception of one rat, a dose of 1 mg/
kg did not produce any sedative effects with either formulation.
Animals in this group looked sluggish and with periods of
inactivity and losing balance, taking an average of 3 to 4 minutes
to make a full recovery. At a dose of 2 mg/kg, arousal levels were
3.5 ± 1.0 and 4.0 ± 0.0 while the times for recovery from LORR
were 3.5 ± 0.2 and 4.5 ± 0.7 minutes for MDCO-700-F1and MDCO-
700-F2, respectively. Time of emergence was an average of2.7
minutes, the time to sternal recumbency was about 3 minutes,
and all animals exhibited a full recovery 6 minutes after the
injection for both formulations.
Table 4: Assessment of sedative effects and duration of action after a single intravenous bolus dose of MDCO-700-F1. The parameters are reported as mean ± SD.
Dose |
Arousal Level |
Time to |
Time to Sternal Recumbency |
Time to Recover Righting Reflex |
Time to Return to Normal |
1 |
5.0 ± 0.0 |
0.0 ± 0.0 |
1.2 ± 1.4 |
1.4 ± 1.6 |
4.3 ± 0.2 |
2 |
3.5 ± 1.0 |
2.7 ± 0.6 |
3.2 ± 1.4 |
3.5 ± 0.2 |
5.7 ± 0.7 |
3 |
1.5 ± 0.0 |
4.4 ± 1.3 |
5.4 ± 1.4 |
5.4 ± 1.4 |
9.7 ± 1.1 |
4 |
1.0 ± 0.0 |
5.1 ± 1.0 |
5.2 ± 0.9 |
5.5 ± 0.7 |
8.3 ± 0.3 |
6 |
1.0 ± 0.0 |
5.7 ± 0.4 |
6.1 ± 0.5 |
6.8 ± 0.5 |
10.1 ± 1.3 |
Table 5: Assessment of sedative effects and duration of action after a single intravenous bolus dose of MDCO-700-F2. The parameters are reported as mean ± SD.
Dose |
Arousal Level |
Time to |
Time to Sternal Recumbency |
Time to Recover Righting Reflex |
Time to Return to Normal |
1 |
4.8 ± 0.5 |
0.4 ± 0.8 |
0.5 ± 1.6 |
0.8 ± 1.7 |
2.7 ± 1.2 |
2 |
4.0 ± 0.0 |
2.7 ± 0.3 |
3.3 ± 0.7 |
4.5 ± 0.7 |
5.9 ± 0.9 |
3 |
1.5 ± 0.0 |
3.9 ± 0.2 |
4.6 ± 0.2 |
5.4 ± 0.2 |
8.4 ± 0.9 |
4 |
1.0 ± 0.0 |
6.2 ± 0.3 |
6.2 ± 0.3 |
6.6 ± 0.5 |
8.7 ± 0.3 |
6 |
1.0 ± 0.0 |
6.6 ± 0.8 |
6.7 ± 0.8 |
7.6 ± 1.0 |
10.3 ± 1.2 |
At a dose of 3 mg/kg, the average arousal levels were 1.5 for
both formulations. The average time to emergence was 4.4 and
3.9 minutes for MDCO-700-F1 and MDCO-700-F2, respectively.
The average time to sternal recumbency and recovery from LORR
were 5.0 and 5.4 minutes, respectively. Compared to doses of 1 and
2 mg/kg, times to emergence, sternal recumbency, and recovery
from LORR were significantly increased for both formulations at
the 3 mg/kg dose (p< 0.0001).
Maximum sedative effects and duration of action were observed at doses of 4 and 6 mg/kg for both formulations. Animals were fully unconscious with a time to emergence of roughly, 6 minutes. There was no significant difference in time to emergence between the doses (p = 0.155 to 0.748). At the 4 mg/ kg dose, the time required for full recovery averaged 8.5 minutes for both formulations. At 6 mg/kg, the time to full recovery for both formulations was 10 minutes which is significantly greater than that observed at 4 mg/kg ( p = 0.025).
Maximum sedative effects and duration of action were observed at doses of 4 and 6 mg/kg for both formulations. Animals were fully unconscious with a time to emergence of roughly, 6 minutes. There was no significant difference in time to emergence between the doses (p = 0.155 to 0.748). At the 4 mg/ kg dose, the time required for full recovery averaged 8.5 minutes for both formulations. At 6 mg/kg, the time to full recovery for both formulations was 10 minutes which is significantly greater than that observed at 4 mg/kg ( p = 0.025).
Figure 1: Relationship between dose and arousal level after intravenous
bolus of MDCO-700.
Figure 2: Relationships between dose and duration of action after an
intravenous bolus of MDCO-700 in Sprague-Dawley rats.
Figure 2A: Time to emergence.
Figure 2A: Time to emergence.
The relationship between the dose and arousal level for
both formulations are shown in Fig 1. Arousal levels were
dose-dependent with a maximum level at 4 mg/kg for both
formulations. There was no significant difference in the arousal
Figure 2B: Time to sternal recumbency.
Figure 2C: Time to recover from LORR.
Figure 2D: Time to full recovery
level (p>0.05) between the two formulations across the dosing
range tested. As shown in Table 6, the calculated values for 50%
of maximal effect (EC50) for arousal level were 2.39 and 2.18
for MDCO-700-F2 and MDCO-700-F1, respectively. The EC50
values for time to emergence, time to sternal recumbency, time
to recovery from LORR and full recovery were similar for both
formulations (Table 6). Overall, both formulations produced
equivalent anesthetic effects and times to recovery.
Table 6: The 50% of maximal effect (EC50) values for arousal level, time to emergence, time to Sternal recumbency, time to recovery of LORR and time to normal after a bolus of MDCO-700-F1 or MDCO-700-F2
Parameter |
EC50 |
|
MDCO-700-F1 |
MDCO-700-F2 |
|
Arousal Level (1-5) |
2.18 |
2.39 |
Time to Emergence (min) |
2.10 |
2.38 |
Time to Sternal Recumbency (min) |
1.84 |
2.22 |
Time to Recover Righting Reflex (min) |
1.99 |
1.92 |
Time to Return to Normal (min) |
1.57 |
1.74 |
Discussion
Etomidate was introduced in 1972 for the induction and
maintenance of anesthesia due to its rapid sedative-hypnotic
effect. Despite minimal hemodynamic changes or respiratory
depression, its clinical utility is limited due adrenal toxicity
associated with long infusions. MDCO-700 (cyclopropylmethoxycarbonyl
metomidate) displays rapid sedative-hypnotic
effects like etomidate, but with minimal adrenocortical
suppression and as such, is a good candidate for further
development [4].
As MDCO-700 was found to be relatively unstable in an aqueous solution, MDCO-700-F1 (10 mg/ml concentration formulated in 10% SBEβCD at a pH of 3.0) was developed and used for early Phase 1 clinical trials. While the formulation was stable, it required storage at -20°C which is less than ideal for a commercial product. MDCO-700-F2 was developed in order to address this liability. MDCO-700-F2 is formulated at 4 mg/mL in 10% SBEβCD at a pH of 5.5. These changes in the formulation maintain overall product stability while allowing for storage under refrigerated conditions (2 – 8°C) instead of frozen at -20°C.
Our study was designed to compare the anesthetic effects and time to recovery for these two formulations in Sprague-Dawley rats. The data from this study demonstrate that both formulations produced equivalent depth of anesthesia (arousal level), time to emergence from anesthesia, time to sternal recumbency, time to recover from loss of righting reflex, and time to return to normal. Based on these results, further clinical development with the new formulation, MDCO-700-F2, is warranted.
As MDCO-700 was found to be relatively unstable in an aqueous solution, MDCO-700-F1 (10 mg/ml concentration formulated in 10% SBEβCD at a pH of 3.0) was developed and used for early Phase 1 clinical trials. While the formulation was stable, it required storage at -20°C which is less than ideal for a commercial product. MDCO-700-F2 was developed in order to address this liability. MDCO-700-F2 is formulated at 4 mg/mL in 10% SBEβCD at a pH of 5.5. These changes in the formulation maintain overall product stability while allowing for storage under refrigerated conditions (2 – 8°C) instead of frozen at -20°C.
Our study was designed to compare the anesthetic effects and time to recovery for these two formulations in Sprague-Dawley rats. The data from this study demonstrate that both formulations produced equivalent depth of anesthesia (arousal level), time to emergence from anesthesia, time to sternal recumbency, time to recover from loss of righting reflex, and time to return to normal. Based on these results, further clinical development with the new formulation, MDCO-700-F2, is warranted.
ReferencesTop
- Ge R, Pejo E, Gallin H, Jeffrey S, Cotten JF and Raines DE. The pharmacology of cyclopropyl-methoxycarbonyl metomidate: a comparison with propofol. Anesth Analg. 2014;118(3):563-567. Doi: 10.1213/ANE.0000000000000069.
- Forman SA. Clinical and molecular pharmacology of etomidate. Anesthesiology . 2011;114(3):695-707. Doi:10.1097/ALN.0b013e3181ff72b5.
- Allolio B, Stuttmann R, Leonhard U, Fischer H and Winkelmann W. Adrenocortical suppression by a single induction dose of etomidate. Klin Wochenschr. 1984;62(21):1014-1017.
- Campagna JA, Pojasek K, Grayzel D, Randle Jand Raines DE. Advancing novel anesthetics: pharmacodynamic and pharmacokinetic studies of cyclopropyl-methoxycarbonyl metomidate in dogs. Anesthesiology. 2014;121(6):1203-1216. Doi: 10.1097/ALN.0000000000000416.
